Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
Summary
Antengene announced an exclusive global license agreement with K2 Therapeutics for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager for solid tumors. The company also signed an option agreement for an undisclosed preclinical bispecific TCE candidate. Antengene will receive about USD 20 million in upfront and near-term consideration across the two deals, plus up to USD 960.5 million in potential milestones for each program and future royalties. K2 Therapeutics gains global rights outside Greater China, and the transaction expands the reach of Antengene's AnTenGager platform.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected